Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale (COMPETE)
Patent Foramen Ovale, Migraine
About this trial
This is an interventional treatment trial for Patent Foramen Ovale focused on measuring Migraine, Patent Foramen Ovale, Medication therapy
Eligibility Criteria
Inclusion Criteria:
- Age 18-65 ;
- Diagnosed migraine by ICHD-3
- History of migraine longer than 1 year
- TCD/TTE/TEE diagnosed patent foramen ovale
- Willing to participant and agree to follow-ups
Exclusion Criteria:
- Migraine caused by other reason
- Had TIA/stroke history
- Hypersensitive or hyposensitive to the study drug
- With a history of anticoagulation or anti-platelet drug intake 3 month before randomization.
- With a history of metoprolol intake 3 month before randomization, and migraine attacks did not reduced 50%.
Sites / Locations
- Fuwai HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Experimental
Experimental
Migraine Medication Group
Anticoagulation or anti-platelet medication Group 1
Anticoagulation or anti-platelet medication Group 2
Anticoagulation or anti-platelet medication Group 3
Patients randomized into migraine medication group will be given Metoprolol 25mg twice a day as the control group.
Patients randomized into anticoagulation or anti-platelet medication group will be given aspirin.
Patients randomized into anticoagulation or anti-platelet medication group will be given clopidogrel.
Patients randomized into anticoagulation or anti-platelet medication group will be given Rivaroxaban.